Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Pfizer Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.88, while Pfizer Inc trades at $24.85 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | PFE | |
|---|---|---|
52-Week High | $112.91 | $28.56 |
52-Week Low | $106.96 | $23.29 |
Market Cap | — | $141.06B |
Volume | — | 29,869,932 |
Sector | — | Health |
Enterprise Value | — | $191.72B |
Dividend Yield | — | 6.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $107.15, down 0.38% with a bearish technical signal from moving averages. Recent dividend payments include $0.42 in May 2026 and $0.41 in June 2026, reflecting steady income distribution. The fixed income ETF sector shows renewed investor interest amid economic resilience and rate uncertainty, as noted by ETF Trends on July 14, 2026.
Outlook remains cautious due to technical weakness and Federal Reserve policy risks. Opportunities exist for income-focused investors seeking corporate bond exposure, but rising rate expectations pose headwinds. Key risks include inflation persistence and narrowing market breadth impacting bond valuations.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
